Safety and Efficacy of 4 mg.kg-1 Sugammadex for Simultaneous Pancreas-Kidney Transplantation Recipients: A Prospective Randomized Trial.
Tang, J., et al.Annals of Transplantation 2023; 28: e940211.
Aims
The aim of this study was to determine the effect of sugammadex in simultanous pancreas-kidney (SPK) transplant recipients.
Interventions
Participants were randomised to receive either a sugammadex injection or the neostigmine-atropine complex.
Participants
50 SPK transplant recipients.
Outcomes
The main outcomes of interest included assessment of blood glucose, serum creatinine, creatinine clearance rate, mean arterial pressure, serum amylase, heart rate, time from sugammadex/neostigmine administration at the scheduled time to recovery, and post-acute pulmonary complications.
Follow-up
108 hours following surgery
CET Conclusions
This is a small randomised controlled trial in anaesthesia for simultaneous kidney-pancreas transplantation. Reversal of neuromuscular blockade with sugammadex is compared to neostigmine. There is great detail in the methods regarding the anaesthetic procedures and processes but there is no description of the randomisation or blinding. The study was powered for a significant improvement in the number of patients reaching TOFratio >0.9 within 40 minutes (essentially the reversal of neuromuscular blockade). There was a significantly faster reversal of neuromuscular blockade with sugammadex administration than neostigmine (median 3 minutes versus median 12 minutes). Time to extubation and length of PACU stay were also significantly reduced. There were no safety concerns in terms of renal function or other complications, but only 7 days follow up is reported.
Data analysis
Modified intention-to-treat analysis
Trial registration
N/A